EP0950413A3 - Verwendung von Sulodexid und Arzneimittel die es enthalten zur Behandlung von diabetischer Retinopathie - Google Patents

Verwendung von Sulodexid und Arzneimittel die es enthalten zur Behandlung von diabetischer Retinopathie Download PDF

Info

Publication number
EP0950413A3
EP0950413A3 EP99103981A EP99103981A EP0950413A3 EP 0950413 A3 EP0950413 A3 EP 0950413A3 EP 99103981 A EP99103981 A EP 99103981A EP 99103981 A EP99103981 A EP 99103981A EP 0950413 A3 EP0950413 A3 EP 0950413A3
Authority
EP
European Patent Office
Prior art keywords
sulodexide
treatment
medicines containing
diabetic retinopathy
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99103981A
Other languages
English (en)
French (fr)
Other versions
EP0950413A2 (de
Inventor
Ernesto Palazzini
Flavia Rubbi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Publication of EP0950413A2 publication Critical patent/EP0950413A2/de
Publication of EP0950413A3 publication Critical patent/EP0950413A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP99103981A 1998-04-15 1999-03-10 Verwendung von Sulodexid und Arzneimittel die es enthalten zur Behandlung von diabetischer Retinopathie Withdrawn EP0950413A3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98BO000239A IT1299969B1 (it) 1998-04-15 1998-04-15 Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
ITBO980239 1998-04-15

Publications (2)

Publication Number Publication Date
EP0950413A2 EP0950413A2 (de) 1999-10-20
EP0950413A3 true EP0950413A3 (de) 1999-12-08

Family

ID=11343111

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99103981A Withdrawn EP0950413A3 (de) 1998-04-15 1999-03-10 Verwendung von Sulodexid und Arzneimittel die es enthalten zur Behandlung von diabetischer Retinopathie

Country Status (9)

Country Link
US (1) US6080732A (de)
EP (1) EP0950413A3 (de)
JP (1) JP4578593B2 (de)
AU (1) AU755534B2 (de)
CA (1) CA2267543C (de)
IL (1) IL128966A (de)
IT (1) IT1299969B1 (de)
NZ (1) NZ334660A (de)
ZA (1) ZA992406B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI991503A1 (it) * 1999-07-08 2001-01-08 Bidifarm S R L Uso di metaboliti oligosaccaridici di proteoglicani come maker in fluidi biologici di diagnosi del biabete e delle complicanze patologiche c
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US20060058268A1 (en) * 2004-07-01 2006-03-16 Sundell Cynthia L Compounds and methods for treating diabetic vascular diseases
WO2007014155A2 (en) * 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
IT1401253B1 (it) * 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624374A1 (de) * 1993-05-10 1994-11-17 ALFA WASSERMANN S.p.A. Verwendung von Sulodexide und von Arzneimitteln, die dieses enthalten, zur Behandlung von Nephropathie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624374A1 (de) * 1993-05-10 1994-11-17 ALFA WASSERMANN S.p.A. Verwendung von Sulodexide und von Arzneimitteln, die dieses enthalten, zur Behandlung von Nephropathie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGUILAR BARTOLOME J.M.: "[First results with the topical application of sulodexide in ophthalmology]. PRIMEROS RESULTADOS DE LA APLICACION TOPICA DE SULODEXIDE EN OFTALMOLOGIA.", ARCHIVOS DE LA SOCIEDAD ESPANOLA DE OFTALMOLOGIA, (1990) 58/2 (51-59)., XP002117943 *
GADDI, A. ET AL: "Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease", J. INT. MED. RES. (1996), 24(5), 389-406, XP002117945 *
RUBBI ET AL.: "Retinal Vein occlusions: clinical study of treatment with sulodexide", EUR. J. CLIN. RES., vol. 4, 1993, pages 19 - 27, XP002117949 *
VORONTSOV A.V. ET AL: "glycosaminoglycans in therapy of diabetic nephropathy", PROBLEMY ENDOKRINOLOGII, vol. 42, no. 5, 1996, pages 14 - 18, XP002117944 *

Also Published As

Publication number Publication date
ITBO980239A1 (it) 1999-10-15
ITBO980239A0 (it) 1998-04-15
IL128966A0 (en) 2000-02-17
EP0950413A2 (de) 1999-10-20
JPH11349486A (ja) 1999-12-21
AU755534B2 (en) 2002-12-12
US6080732A (en) 2000-06-27
IT1299969B1 (it) 2000-04-04
CA2267543C (en) 2008-02-12
ZA992406B (en) 1999-10-01
IL128966A (en) 2003-05-29
CA2267543A1 (en) 1999-10-15
NZ334660A (en) 2000-10-27
AU2246299A (en) 1999-10-28
JP4578593B2 (ja) 2010-11-10

Similar Documents

Publication Publication Date Title
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
WO2000038760A3 (en) Rheological treatment methods and related apheresis systems
SE9702860L (sv) Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
FR11C0006I1 (fr) Administration amelioree de medicaments sur des muqueuses
UA41989C2 (uk) Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри
EP1019072A4 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
GB0410266D0 (en) Treatment of apoptosis
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
NZ501950A (en) Medicinal compositions for application to mucosa
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
ME00578A (en) Use of gastrointestinal lipase inhibitors
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
DE69841200D1 (de) Oxalate-abbauende mikroorganismen oder oxalate-abbauende enzyme zur verhütung der oxalate-verwandten krankheiten
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
EP0950413A3 (de) Verwendung von Sulodexid und Arzneimittel die es enthalten zur Behandlung von diabetischer Retinopathie
CA2587081A1 (en) Compositions for treatment of ear infections
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
DE60302431D1 (de) Methode zur behandlung eines analgesiebedürftigen patienten
WO2002065989A3 (en) Aminoglycoside treatment for lysosomal storage diseases
EE04330B1 (et) Levosimendani transmukoossed koostised ja nende kasutamine ravimi valmistamiseks
ATE482715T1 (de) Pharmazeutischen zubereitungen von inhibitoren der aminopeptidase n gegebenenfalls in kombination mit inhibitoren der dipeptidylpeptidase iv zur therapie und prävention dermatologischer erkrankungen mit sebozytärer hyperproliferation und veränderten differenzierungszuständen
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

AKX Designation fees paid
REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000825